Committed to Eliminating HCV and Transforming Lives
This non-promotional webpage has been developed by Gilead Sciences Ltd.
UKI-UNB-1665 | September 2025
At Gilead, our mission is to help eliminate HCV and advance health equity to create a healthier future for those impacted by viral hepatitis. Through close collaboration with the NHS, drug and alcohol services, prison services, and community organisations, we strive to expand access to care while addressing critical challenges in liver health.
For decades, we have focused on driving scientific innovation to help improve care, making cure, and even elimination a potential reality.
​
To find out more about Gilead’s commitment to HCV Elimination, visit the BeFreeofHepC webpage via the link below.
ABOUT
Please note, Gilead Sciences Ltd. have provided sponsorship of this event but provided no input into the programme.
The views and opinions of the speakers are not necessarily those of Gilead Sciences Ltd.
Reporting suspected adverse reactions of medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals and patients are asked to report any suspected adverse reactions via the national reporting line: Yellow Card Scheme available at: www.mhra.gov.uk/yellowcard. Adverse reactions may also be reported directly to Gilead. Adverse reactions related to Gilead products may be reported directly to Gilead via 01223 897 555 or by email to ukmedinfo@gilead.com.